Livagen (KEDA)

What is Livagen?

Livagen (KEDA) is the synthetic tetrapeptide bioregulator that bridges the liver and haematopoietic blood systems — the only compound in the Khavinson series with a dual-organ primary target. The sequence Lys-Glu-Asp-Ala (KEDA) interacts with chromatin in both hepatocytes and haematopoietic blood cells (erythrocytes, lymphocytes), activating gene expression programs relevant to both organ systems simultaneously.

The liver-blood connection is physiologically important. The liver is the primary producer of most plasma proteins, performs haem recycling from aged red blood cells, produces thrombopoietin (the primary regulator of platelet production), and is deeply integrated with haematopoietic function. Livagen's simultaneous targeting of liver and blood cell chromatin reflects this functional integration.

As a Cytogen (synthetic peptide), Livagen offers precision and injectability advantages: defined KEDA sequence with characterised mechanisms, subcutaneous injection for direct systemic delivery, faster onset than oral Cytomax courses. For users who prefer injectable protocols or want coverage between Svetinorm and Bonomarlot Cytomax courses, Livagen provides liver and haematopoietic bioregulator support in injectable format.

How it works

KEDA Sequence — Dual Chromatin Interaction

The KEDA tetrapeptide penetrates cell nuclei in hepatocytes and haematopoietic blood cells, binding to specific AT-rich DNA sequences and modifying chromatin architecture. In hepatocytes, KEDA activates gene expression for detoxification enzymes, hepatocyte survival signalling, and anti-fibrotic gene regulation. In haematopoietic cells, KEDA activates gene expression for red blood cell maturation, haemoglobin synthesis, and lymphocyte function maintenance. The dual organ targeting from one tetrapeptide reflects shared regulatory DNA motifs across these physiologically connected organ systems.

The One Amino Acid Difference — KEDA vs. KED (Vesugen)

Vesugen = KED = Lys-Glu-Asp (three amino acids) — targets vascular endothelium. Livagen = KEDA = Lys-Glu-Asp-Ala (four amino acids, adding Alanine) — targets liver and blood. The addition of a single amino acid shifts the primary chromatin binding specificity from vasculature to hepatocytes and haematopoietic cells. This is one of the clearest demonstrations of the Cytogen organ-specificity principle — minor sequence variations produce dramatically different tissue targeting.

Liver Detoxification Support

In hepatocytes, KEDA's chromatin interaction activates Phase I and Phase II detoxification enzyme expression — CYP450 isoforms, UDP-glucuronosyltransferases, and glutathione S-transferases. This supports the liver's primary function of processing, metabolising, and eliminating xenobiotics, drugs, and metabolic waste products.

What the research shows

Community knowledge

Livagen is used primarily by users who prefer injectable Cytogens over oral Cytomaxes, or who want coverage in the months between Svetinorm and Bonomarlot courses. It is viewed as the efficiency option — one injectable compound covering two organ systems rather than running separate oral Cytomax courses.